BurdEn of NEw Onset Atrial FIbrillation in patienTs With Acute Myocardial Infarction
Recruiting
Observational Study
Atrial Fibrillation New Onset
Acute Myocardial Infarction
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 774 (estimated)
- Sponsor
- Shanghai 10th People's Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
To validate the prognostic importance of the burden of new-onset atrial fibrillation (NOAF) complicating acute myocardial infarction (AMI) in a prospectively designed hospital-based registry. To characterize those factors that contribute to the progression of post-MI NOAF burden. To establish a prediction model for the risk stratification of patients with NOAF complicating AMI. To explore the clin…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adult patients (\>18 years old);
* Patient with AMI (including STEMI and NSTEMI) who developed NOAF during the index hospitalization;
* Patients must have received in-hospital CEM for at least 5 days;
* Patients must give informed consent.
Exclusion Criteria:
* Patients with…
Contacts